Document:

EX-10.1

 Exhibit 10.1 

Execution Copy 
 PENTAIR
PLC 
 P.O. Box 471, Sharp Street, Walkden 

Manchester, M28 8BU 

United Kingdom 

September 7, 2015 
 Mr. Edward P.
Garden 
 Mr. Matthew Peltz 
 Mr. Brian Baldwin 

Trian Fund Management, L.P. 
 280 Park Avenue, 41st Floor 
 New York, New York 10017 

Dear Ed, Matthew and Brian: 
 1. (a) Pentair plc
(“Pentair” or the “Company”) hereby agrees that (i) (A) at its annual general meeting of shareholders in 2016 or any special meeting of shareholders called by the Company prior to such annual general meeting (each, the
“Shareholder Meeting”), Pentair shall submit to its shareholders a resolution to amend Section 71 of Pentair’s articles of association to increase the maximum size of the board of directors of Pentair (the “Board”) by
one director to twelve (12) directors (the “Amendment Resolution”), (B) the Board shall recommend that the shareholders of Pentair vote for the Amendment Resolution, and the Company and the Board shall take any other necessary
action to ensure that the Amendment Resolution may be approved by an Ordinary Resolution (as defined in the Articles of Association), (C) the Company shall use its reasonable best efforts (which shall include the solicitation of proxies) to
obtain the approval of the Amendment Resolution by the shareholders of the Company (it being understood that such efforts shall not be less than the efforts used by the Company to obtain the election of the directors nominated by the Board for
election at the Shareholder Meeting (or, in the case of a special meeting of shareholders, the efforts used by the Company to obtain shareholder approval for any other action recommended by the Board)) and (D) immediately after the Shareholder
Meeting, the Board shall (conditional on the passage of the Amendment Resolution) appoint EPG as director to fill the resulting vacancy on the Board and appoint EPG as a member of Pentair’s Compensation Committee (the “Compensation
Committee”), with each such appointment becoming effective from and after the date of the Shareholder Meeting, (ii) beginning on or prior to September 21, 2015 (the “Commencement Date”), until the date of the Shareholder
Meeting, EPG will have the right, subject to the limitations set forth in paragraph 1(c) of this letter and applicable laws and governmental regulations, to attend (in person or by teleconference or videoconference), and participate in, all meetings
of the Board (and all meetings of the Compensation Committee) in a non-voting participant capacity (but EPG’s presence shall not be counted towards the quorum of the Board or the Compensation Committee) and (iii) beginning on the
Commencement Date, until the later of (A) the date of the Shareholder Meeting and (B) if EPG is appointed as director of Pentair on the date of the Shareholder Meeting, the date EPG (or any other employee of Trian Fund Management, L.P.
(“Trian”)) is no longer a director of Pentair (such date, the “Termination Date”), either of Matthew Peltz or Brian Baldwin (such individual (who may vary from meeting to meeting and may be determined by Trian in its sole
discretion), when acting in his capacity as 

 Trian Fund Management, L.P. 

September 7, 2015 
  Page
 2
 
  

 
a Board observer of the Company, the “Board Observer”) shall have the right, subject to the limitations set forth in this letter and applicable laws and governmental regulations, to
attend (in person or by teleconference or videoconference) all meetings of the Board (and all meetings of the Compensation Committee) in a non-voting, non-participating observer capacity (but the Board Observer’s presence shall not be counted
towards the Board’s or the Compensation Committee’s quorum); provided, that, in the event that the Board or the Compensation Committee, as applicable, determines to hold an executive session (which EPG shall be entitled to attend
regardless of whether he is a director or Board participant at the time) (an “Executive Session”), and the Board or the Compensation Committee, as applicable, (acting reasonably and in good faith) determines that it would not be
appropriate for the Board Observer to attend such Executive Session or any portion thereof, the Board Observer shall not have the right to attend, and shall recuse himself from, such Executive Session or portion thereof to the extent requested by
the Board or the Compensation Committee, as applicable. To facilitate the appointment of EPG as a Board participant and director, the Board will, simultaneously with the adoption of the resolutions providing for the matters described in clauses
(i) through (iii) above (which shall be adopted on the Commencement Date), also adopt certain other enabling resolutions mutually acceptable to Trian and Pentair (the “Facilitating Resolutions”). 

(b) The Company shall provide EPG in his capacity as a participant pursuant to clause (ii) of paragraph 1(a) of this letter and, until
the Termination Date, the Board Observer, with (x) notice of all meetings of the Board and the Compensation Committee, including notice of time and place of any such meetings, (y) all written materials or other correspondence delivered to
the members of the Board or the Compensation Committee, as the case may be, for consideration at such meetings or any other purpose, and (z) all proposed written consent actions provided to the Board or the Compensation Committee, as the case
may be, in each case, at the same time and in the same manner such notice and information is delivered to the members of the Board; provided, that the failure to provide or make available one or more items described in this paragraph 1(b) shall not
affect the validity of any action taken by the Board or the Compensation Committee. 
 (c) Notwithstanding the foregoing, as long as EPG
participates in Board meetings in a participant capacity pursuant to clause (ii) of paragraph 1(a) of this letter, (A) the Company shall have the right to withhold any notice or information from EPG or the Board Observer and to exclude EPG
or the Board Observer from any meeting of the Board or the Compensation Committee or any portion thereof to the extent access to such information or attendance at such meeting or any portion thereof could reasonably be expected to remove the
attorney-client privilege between the Company and its counsel; and (B) each of EPG and the Board Observer shall be required to recuse himself from any portion of any Board or Compensation Committee meeting if either EPG or the Board Observer
would be required to recuse himself from such portion of the meeting under applicable law, governmental regulations or the Company’s policies and procedures if he had been a director of the Company at the time. Notwithstanding anything in this
letter to the contrary, unless otherwise consented to in writing by each of the other parties to this letter, the rights of each of EPG and the Board Observer pursuant to clause (ii) and clause (iii), respectively, of paragraph 1(a) of this
letter shall be personal to each of them and shall not be assigned or otherwise transferred by any of them to any other person under any circumstances, and any purported assignment or transfer by any of them

 Trian Fund Management, L.P. 

September 7, 2015 
  Page
 3
 
  

 
of their respective rights pursuant to clause (ii) or clause (iii), as applicable, of paragraph 1(a) of this letter shall be null and void ab initio and shall have no effect. For as
long as EPG attends Board or Compensation Committee meetings in a participant capacity pursuant to clause (ii) of paragraph 1(a) of this letter, the Company shall reimburse EPG for expenses incurred in connection with his attendance at such
meetings to the same extent and in the same manner as it reimburses the directors of the Company. In addition, beginning at such time as EPG becomes a director of the Company pursuant to clause (i) of paragraph 1(a) of this letter, EPG shall be
entitled to receive compensation and expense reimbursement to the same extent and in the same manner as the other directors of the Company. The Company acknowledges that EPG may (1) exercise, assign, sell or otherwise transfer (or hold for the
benefit of another party) any securities of the Company that he has been or may be granted under the Company’s incentive plans or otherwise as directed by Trian or its designee and (2) assign, convey and deliver to (or hold for the benefit
of) Trian or its designee all stock or other property (including, without limitation, cash) received upon such exercise, assignment or sale or other transfer. In addition, the Company confirms that any Pentair securities held by Trian or the
investment funds or vehicles that it advises, manages or controls (collectively, the “Trian Funds”) shall be deemed to be held by EPG for purposes of the director stock ownership requirements contained in Pentair’s Corporate
Governance Principles and/or any other applicable policies of Pentair. From and after the date of this letter agreement, the Company agrees that EPG shall be covered under the Company’s directors’ and officers’ liability insurance
policies for his service as a director and Board participant and each of EPG, Mathew Peltz and Brian Baldwin shall be covered under contractual indemnification agreements for his service as a director, or Board participant or Board observer, as
applicable, in each case, to the same extent and in the same manner as the directors of the Company. Except as described above, the Board Observer shall not be entitled to receive any compensation or expense reimbursement from the Company for his
attendance at meetings of the Board or the Compensation Committee. 
 2. Promptly following the execution of this letter, Pentair and Trian
will issue a joint press release substantially in the form attached hereto as Exhibit A. 
 3. (a) You acknowledge that you are
sensitive to Pentair’s concerns regarding confidentiality and other regulatory issues, and you agree to restrict yourselves as set forth in this letter in order to address those considerations. To that end, you hereby undertake, except to the
extent legally required, to refrain from directly or indirectly communicating or disclosing to anyone confidential or non-public information that you learn in your capacity as a participant or observer in Board or Compensation Committee meetings or
as a director of Pentair, as applicable; provided, that you may communicate such information to personnel of Trian and to Trian’s outside legal, tax, insurance and accounting advisors (such personnel of Trian and such advisors, together with
such advisory firms, the “Trian Associates”) that need to know such information for purposes of the analysis of Trian’s investment in Pentair and/or a review of the financial and business affairs of the Company on your or Trian’s
behalf; provided, further, that Trian shall be (and shall cause the Trian Associates to be) bound by these same confidentiality restrictions applicable to you, with respect to all confidential or non-public information conveyed by you, or by or on
behalf of the Company or any of its representatives, to Trian or to any Trian Associates. Trian agrees that it shall be responsible for any breach of this letter by Trian, the Trian Funds and the Trian Associates. 

 Trian Fund Management, L.P. 

September 7, 2015 
  Page
 4
 
  

 (b) For purposes of this letter, information shall not be considered confidential or
non-public information where: (i) it becomes or was available to the public other than as a result of disclosure by you, Trian or a Trian Associate in breach of this letter; (ii) it was available to you, Trian or a Trian Associate prior to
being communicated or disclosed to you, Trian or a Trian Associate by the Company or one of its directors, officers, employees, advisors or representatives (collectively, “Company Agents”), provided that such information is not known by
you, Trian or such Trian Associate to be subject to a legal, contractual or fiduciary obligation of confidentiality to the Company; (iii) it is or becomes available to you, Trian or a Trian Associate from a source other than the Company or a
Company Agent, provided the source is not known by you, Trian or such Trian Associate to be prohibited from transmitting the information by a confidentiality agreement with the Company or any other contractual, legal or fiduciary obligation of
confidentiality to the Company; or (iv) it was independently developed by you, Trian or a Trian Associate without the benefit of confidential or non-public information received from the Company or a Company Agent in connection with your
participation in Board or Compensation Committee meetings in a participant or observer capacity or service as a director, as applicable. 

(c) In the event you, Trian or a Trian Associate (each, a “Receiving Party”) receives a request or is required by legal, judicial or
administrative process (including interrogatories, oral questions, court or stock exchange, subpoena, civil investigative demand or similar legal process), or receives a request from a governmental, regulatory or supervisory authority, court or
stock exchange to disclose any confidential or non-public information received from the Company or a Company Agent in connection with your participation in Board or Compensation Committee meetings in a participant or observer capacity or service as
a director, as applicable, each of you or Trian, as applicable, agree to, as promptly as practicable, to the extent not prohibited by law, to notify the Company of such a requirement or request, so that the Company may seek, at the Company’s
expense, an appropriate protective order and/or waive compliance with the terms of this letter. In the event such protective order or other protection is denied and a Receiving Party is nonetheless legally compelled or requested to disclose such
information, it may furnish (without any liability under this letter) only that portion of the confidential or non-public information that the Receiving Party’s legal counsel advises is being required and will exercise commercially reasonable
efforts to protect the confidentiality of the remaining information. The Receiving Parties shall be entitled to reimbursement of their reasonable out-of-pocket expenses, including reasonable fees and expenses of legal counsel, for any action taken
by them in connection with this paragraph 3(c) at the Company’s request. 
 (d) In addition, each of you and Trian acknowledges, and
Trian agrees to advise each Trian Associate who is informed of the matters which are the subject of this letter, that the confidential or non-public information that is subject to the confidentiality provisions herein may constitute material
non-public information under applicable U.S. federal and state securities laws, and that the U.S. securities laws prohibit any person who has received from an issuer such material non-public information from purchasing or selling securities of such
issuer while in possession of such material non-public information. 

 Trian Fund Management, L.P. 

September 7, 2015 
  Page
 5
 
  

 (e) Each of you and Trian agrees that any proprietary information of the Company received
from or on behalf of the Company shall remain the property of the Company. None of you, Trian and the Trian Associates shall, by virtue of the Company’s disclosure of, or your, Trian’s or any Trian Associates’ use of, any such
proprietary information, acquire any rights with respect thereto, all of which rights (including all intellectual property rights) shall remain exclusively with the Company. 

(f) Furthermore, except as otherwise agreed in writing by the Company (whether before or after the date hereof), (i) EPG agrees that, as
long as he participates in Board or Compensation Committee meetings in a participant (non-director) capacity, he will comply with the Company’s Insider Trading Policy, Corporate Governance Principles, External Communications and Disclosure
Policy, Related-Person Transactions Approval Policy, and, to the extent the Mr. Garden is acting in his capacity as a participant, the Company’s Anti-Bribery Policy, Political Contributions Policy, Procedures Governing Interactions with
Government Officials and Third Parties and Code of Business Conduct and Ethics (to the extent that each policy is applicable generally to the Company’s directors and with the understanding that such policies will be applied to EPG on a
reasonable and good faith basis and in a manner consistent with the Facilitating Resolutions) and (ii) each of Matthew Peltz and Brian Baldwin agrees that, until the Termination Date, each will comply with the Company’s Insider Trading
Policy, External Communications and Disclosure Policy, Related-Person Transactions Approval Policy and, to the extent that Mr. Peltz or Mr. Baldwin is acting in his capacity as a Board Observer, the Company’s Code of Business Conduct
and Ethics (insofar as such Code of Business Conduct and Ethics is applicable to Mr. Peltz, Mr. Baldwin or any of their immediate family members that are employed by Trian), Anti-Bribery Policy, Political Contributions Policy, and
Procedures Governing Interactions with Government Officials and Third Parties (to the extent that each policy is applicable generally to the Company’s directors and with the understanding that such policies will be applied to each such
individual on a reasonable and good faith basis and in a manner consistent with the Facilitating Resolutions) (in each case, as such policies are currently in effect, together with changes to such policies applicable to directors of Pentair
generally and applied to you on a reasonable and good faith basis and in a manner consistent with the Facilitating Resolutions). In addition, except as otherwise agreed between Trian and Pentair, Trian will not, and will not permit the Trian Funds
to, engage in the purchase or sale of Pentair securities during Pentair trading blackout periods (under the restriction calendar currently in effect, together with any changes to such calendar or unscheduled blackout periods of which you are made
aware (in either case imposed on a reasonable and good faith basis)) that are applicable to all directors of Pentair. Pentair agrees to notify EPG and Trian in advance when any trading blackout period begins and ends. Pentair shall not be
responsible for compliance by Trian, the Trian Funds, any Trian Associates or you with the securities laws, including regulations relating to insider trading. 

4. This letter (except for paragraphs 4-11 hereof) shall terminate eighteen months after the Termination Date; provided, that if the Company
breaches any of its obligations under paragraph 1(a) in any material respect, paragraph 3 of this letter shall immediately terminate (except that paragraph 3 shall not terminate pursuant to this proviso if: (i) EPG has already been appointed to
the Board pursuant to the terms of paragraph 1(a)(i)(D) or (ii) EPG, Mr. Peltz, Mr. Baldwin or the Receiving Parties are in breach of their obligations under paragraph 3 in any material respect (after being given reasonable notice and
an opportunity to cure such breach) at the time of any such alleged breach by the Company of its obligations under paragraph 1(a)). 

 Trian Fund Management, L.P. 

September 7, 2015 
  Page
 6
 
  

 5. Each party represents and warrants that (a) it has the power and authority to
execute, deliver and carry out the terms and provisions of this letter and to consummate the transactions contemplated hereby and (b) this letter has been duly and validly authorized, executed and delivered by each party, and assuming the due
and valid authorization, execution and delivery by the other parties hereto, constitutes a valid and binding agreement of each party and is enforceable against such party in accordance with its terms. 

6. All attorneys’ fees, costs and expenses incurred in connection with this letter and, except as otherwise provided herein, all matters
related hereto will be paid by the party incurring such fees, costs or expenses. 
 7. Each of the parties bound by this letter consents and
submits to the exclusive jurisdiction of the courts of the State of New York located in the Borough of Manhattan in New York City and the courts of the United States located in the Borough of Manhattan in New York City in the State of New York for
the adjudication of any action or legal proceeding relating to or arising out of this letter (and each such person agrees not to commence any action or legal proceeding relating thereto except in any such court). Each of the parties bound by this
letter irrevocably and unconditionally waives any objection which it may now or hereafter have to the laying of venue in such courts and agrees not to plead or claim in any such court that any such action or legal proceeding brought in any such
court has been brought in an inconvenient forum. Each of the parties bound by this letter agrees that service of any process, summons, notice or document by U.S. registered mail addressed to such person shall be effective service of process for any
such suit, action or proceeding brought against such person in any such court. Each of the parties bound by this letter hereby agrees that a judgment in any such suit, action or proceeding brought in any such court shall be conclusive and binding
upon such person and may be enforced in any other courts to whose jurisdiction such person is or may be subject by suit upon such judgment. 

8. Each party to this letter agrees that money damages would not be a sufficient remedy for any breach of this letter by the other party
hereto, and that the non-breaching party shall be entitled to, and the breaching party shall not oppose (on the basis that there is an adequate remedy at law) the granting of, equitable relief, including injunction and specific performance, in the
event of any such breach, in addition to all other remedies available to the non-breaching party at law or in equity. The breaching party further agrees to waive any requirement for the securing or posting of any bond in connection with such remedy.

 9. No failure or delay by any party hereto in exercising any right, power or privilege hereunder will operate as a waiver thereof, nor
will any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power or privilege hereunder. 

10. This letter and any dispute arising out of or in connection with it or its subject matter or formation (including non-contractual disputes
or claims) shall be governed by and construed in accordance with the laws of New York. 

 Trian Fund Management, L.P. 

September 7, 2015 
  Page
 7
 
  

 11. This letter may be modified or amended only by a separate writing signed by the parties
hereto expressly so modifying or amending this letter. This letter constitutes the entire agreement among the parties with respect to the subject matter hereof and supersedes all prior oral or written agreements or understandings that may exist
between such parties hereto with respect to the subject matter hereof, except as contemplated by the first sentence of paragraph 3(f) of this letter. This letter shall inure to the benefit of and shall be binding upon the parties hereto and their
respective successors and permitted assigns, and nothing herein is intended to confer on any person other than the parties hereto or their respective successors and permitted assigns, any rights, remedies, obligations or liabilities under or by
reason of this letter. The rights and obligations of any party under this letter may not be transferred without the consent of the other parties hereto, and any transfer in violation of this sentence shall be null and void. 

We look forward to working together with you and Trian. 

 
					
	Very truly yours,
	
	PENTAIR PLC
		
	By:	 	 /s/ Angela D. Lageson

		 	Name:	 	Angela D. Lageson
		 	Title:	 	Senior Vice President, General Counsel and Secretary

  

					
	AGREED TO AND ACCEPTED
	AS OF THE DATE FIRST WRITTEN ABOVE
	
	 /s/ Edward P. Garden

	EDWARD P. GARDEN
	
	 /s/ Matthew Peltz

	MATTHEW PELTZ
	
	 /s/ Brian Baldwin

	BRIAN BALDWIN
	
	TRIAN FUND MANAGEMENT, L.P.
		
	By:	 	Trian Fund Management GP, LLC,
		 	its general partner
		
	By:	 	 /s/ Edward P. Garden

		 	Name:	 	Edward P. Garden
		 	Title:	 	Member

 Exhibit A 

Press Release 

PENTAIR TO PROPOSE EXPANSION OF ITS BOARD TO INCLUDE TRIAN’S ED GARDEN 

Garden to be Appointed to Board upon Shareholder Approval 

Manchester, United Kingdom – September 8, 2015 – Pentair plc (NYSE: PNR) today announced that it will recommend to its shareholders that
they approve a resolution at its 2016 annual general meeting of shareholders to increase the size of its Board by one director and will appoint Ed Garden, Chief Investment Officer and a Founding Partner of Trian, to the Pentair Board to fill the
resulting vacancy. With the addition of Mr. Garden, Pentair’s Board will have 12 directors, 11 of whom are independent. In the interim period prior to the 2016 annual general meeting of shareholders, Mr. Garden will be able to attend
and participate in all meetings of Pentair’s Board in a non-voting capacity. The move follows a series of collaborative discussions between Pentair and Trian, one of Pentair’s largest shareholders with a 7.2% ownership position. 

“We have maintained an active and constructive dialogue with Trian regarding our common goal of increasing shareholder value, as we do with all of our
shareholders” said Randall J. Hogan, Pentair’s Chairman and CEO. “We believe the addition of Ed to our board would bring a shareholder’s perspective and we look forward to benefiting from his insights and Trian’s strong
analytical work. Pentair remains focused on driving productivity and identifying strategic opportunities to position our portfolio for long-term growth.” 

Garden added: “Pentair has created significant shareholder value over the past 14 years since Randy Hogan became CEO and has the potential to generate
significant additional value for its shareholders in the years ahead. As one of Pentair’s largest shareholders, Trian looks forward to continuing to work with Pentair to further improve the company’s performance through increased organic
revenue growth, margin enhancement, and accretive acquisitions.” 
 Upon his appointment to the Pentair Board, Garden will join the Compensation
Committee of Pentair’s Board. 
 Ed Garden Biography 

Mr. Garden is Chief Investment Officer and a Founding Partner of Trian. Mr. Garden oversees Trian’s portfolio management, idea generation,
analyses and due diligence activities. Mr. Garden is currently a director of The Wendy’s Company and The Bank of New York Mellon Corporation. Mr. Garden previously served as a director of Family Dollar Stores, Inc. from September 2011
to July 2015. 
 About Pentair plc 
 Pentair plc
(www.pentair.com) delivers industry-leading products, services and solutions for its customers’ diverse needs in water and other fluids, thermal management and equipment protection. With 2014 revenues of $7.0 billion, Pentair employs
approximately 30,000 people worldwide. 
 About Trian Fund Management, L.P. 

Founded in 2005 by Nelson Peltz, Peter May and Ed Garden, Trian seeks to invest in high quality but undervalued public companies and to work constructively
with the management and boards of those companies to significantly enhance shareholder value for all shareholders through a combination of improved operational execution, strategic re-direction, more efficient capital allocation and increased focus.

  
 9 

 Contacts: 

Pentair plc Media Relations 
 Rebecca Osborn 

763-656-5580 
 rebecca.osborn@pentair.com 

Pentair plc Investors 
 Jim Lucas 

763-656-5575 
 jim.lucas@pentair.com 

Trian Media/Investors 
 Anne Tarbell 

212-451-3030 
 atarbell@trianpartners.com 

  
 10EX-4.4

 Exhibit 4.4 

EXECUTION VERSION 

REGISTRATION RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
	 1.
	 	 Definitions
	  	 	1	  
			
	 2.
	 	 Registration Rights
	  	 	4	  
		 	 2.1
	  	 Demand Registration
	  	 	4	  
		 	 2.2
	  	 Company Registration
	  	 	6	  
		 	 2.3
	  	 Underwriting Requirements
	  	 	6	  
		 	 2.4
	  	 Obligations of the Company
	  	 	8	  
		 	 2.5
	  	 Furnish Information
	  	 	9	  
		 	 2.6
	  	 Expenses of Registration
	  	 	9	  
		 	 2.7
	  	 Delay of Registration
	  	 	10	  
		 	 2.8
	  	 Indemnification
	  	 	10	  
		 	 2.9
	  	 Reports Under Exchange Act
	  	 	12	  
		 	 2.10
	  	 Limitations on Subsequent Registration Rights
	  	 	13	  
		 	 2.11
	  	 “Market Stand-off” Agreement
	  	 	13	  
		 	 2.12
	  	 Restrictions on Transfer
	  	 	14	  
		 	 2.13
	  	 Termination of Registration Rights
	  	 	15	  
			
	 3.
	 	 Miscellaneous
	  	 	16	  
		 	 3.1
	  	 Successors and Assigns
	  	 	16	  
		 	 3.2
	  	 Governing Law
	  	 	16	  
		 	 3.3
	  	 Counterparts
	  	 	16	  
		 	 3.4
	  	 Titles and Subtitles
	  	 	16	  
		 	 3.5
	  	 Notices
	  	 	16	  
		 	 3.6
	  	 Amendments and Waivers
	  	 	17	  
		 	 3.7
	  	 Severability
	  	 	17	  
		 	 3.8
	  	 Aggregation of Stock
	  	 	17	  
		 	 3.9
	  	 Additional Investors
	  	 	17	  
		 	 3.10
	  	 Entire Agreement
	  	 	17	  
		 	 3.11
	  	 Dispute Resolution
	  	 	17	  
		 	 3.12
	  	 Delays or Omissions
	  	 	18	  
		 	 3.13
	  	 Acknowledgment by the Company
	  	 	18	  
			
	 Schedule A
	  	 -          Schedule of New Investors
	  			
	 Schedule B
	  	 -          Schedule of Initial Investors
	  			

  
 i 

 REGISTRATION RIGHTS AGREEMENT 

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), is made as of the
4th day of September, 2015, by and among Nabriva Therapeutics AG, a stock corporation (Aktiengesellschaft) incorporated in the Republic of Austria (the “Company”), each of
the new investors listed on Schedule A hereto (the “New Investor”), each of the initial investors listed on Schedule B hereto (the “Initial Investor”), Sandoz GmbH, a limited liability company
incorporated in the Republic of Austria (“Sandoz”, and together with the Initial Investors and the New Investors, the “Investors”) and any additional investor that becomes a party to this Agreement in accordance
with Section 3.9 hereof. 
 RECITALS 

WHEREAS, the Company and the Investors are parties to that certain Investment and Subscription Agreement dated as of March 31,
2015 (the “Subscription Agreement”); 
 WHEREAS, the Company and the Investors are parties to that certain
Shareholders Agreement dated as of April 2, 2015 (the “Shareholders Agreement”); 
 WHEREAS, in order to induce
the Company to enter into the Subscription Agreement and to induce the Initial Investors and the New Investors to invest in the Company pursuant to the Subscription Agreement, the Investors and the Company agreed in the Shareholders Agreement to
enter into a “Registration Rights Agreement” governing the rights of the Investors to cause the Company to register certain securities of the Company issuable to Investors; and 

WHEREAS, the Investors and the Company hereby agree that this Agreement constitutes such “Registration Rights Agreement”
required by the Shareholders Agreement and shall govern the rights of the Investors to cause the Company to register the Common Shares (or American Depositary Shares in respect thereof) issuable to the Investors; 

NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled
by one or more general partners or managing members of, or shares the same management company with, such Person. 
 1.2
“American Depositary Shares” means such securities as may be issued by a depositary of the Company representing its Common Shares and evidenced by American Depositary Receipts. 

1.3 “Common Shares” means the Company’s common shares with a nominal value of €1.00 per share.

 1.4 “Damages” means any loss, damage, claim or liability (joint
or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon:
(i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto;
(ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any
of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.5 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. 
 1.6 “Excluded Registration” means (i) a registration relating to the sale of
securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include
substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; (iv) a registration in which the only Common Shares or American Depositary Shares being
registered are Common Shares or American Depositary Shares issuable upon conversion of debt securities that are also being registered; or (v) a registration relating to the IPO prior to April 2, 2018. 

1.7 “Foreign Private Issuer” means “foreign private issuer” as defined in Rule 405 of the Securities
Act. 
 1.8 “Form F-1” means such form under the Securities Act as
in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. To the extent the Company no longer qualifies as a Foreign Private Issuer, such term shall mean Form S-1 under the Securities
Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.9 “Form F-3” means such form under the Securities Act as in effect
on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. To the extent the Company
no longer qualifies as a Foreign Private Issuer, such term shall mean Form S-3 under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.10 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

  
 2 

 1.11 “Immediate Family Member” means a child, stepchild,
grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.12 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this
Agreement. 
 1.13 “IPO” means the Company’s first underwritten public offering of its Common Shares
(or American Depositary Shares representing such Common Shares) under the Securities Act. 
 1.14 “New
Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may
become, convertible or exchangeable into or exercisable for such equity securities. 
 1.15 “OrbiMed” means
OrbiMed Private Investments V, LP, a limited partnership organized under New York law. 
 1.16 “Person”
means any individual, corporation, partnership, trust, limited liability company, association or other entity. 
 1.17
“Preferred B Shares” means the preferred B shares of the Company issued and sold pursuant to the Subscription Agreement. 

1.18 “Registrable Securities” means (i) the Common Shares issuable or issued upon conversion of the
Preferred B Shares held by the Investors; (ii) the Common Shares held by Sandoz; (iii) any Common Shares, or any Common Shares issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the
Company, acquired by the New Investors after the date hereof and prior to the IPO; and (iv) any Common Shares issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under
this Agreement are not assigned pursuant to Subsection 3.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement.
Notwithstanding the foregoing, the Company shall have the right to determine, at its own discretion, whether such Registrable Securities are registered as Common Shares or American Depositary Shares. 

1.19 “Requisite New Investor” shall mean (a) Vivo, OrbiMed and any one of the other New Investors that is
not an Initial Investor, each of which must continue to hold directly or through their affiliates the Preferred B Shares purchased pursuant to the Subscription Agreement, (b) if one of either Vivo or OrbiMed does not hold Preferred B Shares,
then either Vivo or OrbMed (to the extent they hold Preferred B Shares) and any 

  
 3 

 
one of the other New Investors that is not an Initial Investor, and (c) if neither Vivo nor OrbiMed hold Preferred B Shares, then the holders of at least a majority of the then-outstanding
Preferred B Shares held by all New Investors that are not Initial Investors. 
 1.20 “Registrable Securities then
outstanding” means the number of shares determined by adding the number of outstanding Common Shares that are Registrable Securities and the number of Common Shares issuable (directly or indirectly) pursuant to then exercisable and/or
convertible securities that are Registrable Securities. 
 1.21 “Restricted Securities” means the securities
of the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof. 
 1.22
“SEC” means the Securities and Exchange Commission. 
 1.23 “SEC Rule 144” means Rule 144
promulgated by the SEC under the Securities Act. 
 1.24 “SEC Rule 145” means Rule 145 promulgated by the
SEC under the Securities Act. 
 1.25 “Securities Act” means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder. 
 1.26 “Selling Expenses” means all underwriting discounts,
selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company
as provided in Subsection 2.6. 
 1.27 “Vivo” means Vivo Capital Fund VIII, L.P., a limied
partnership organized under California law and Vivo Capital Surplus Fund VIII, L.P., a limied partnership organized under California law. 

2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form F-1 Demand. If at any time after the earlier of April 2, 2018 or one hundred eighty (180) days after the effective
date of the registration statement for the IPO, the Company receives a request from (i) Holders of at least sixty percent (60%) of the Preferred B Shares or (ii) the Requisite New Investors that the Company file a Form F-1
registration statement with respect to the Registrable Securities then outstanding having an anticipated aggregate offering price, net of Selling Expenses, of at least $10.0 million, then the Company shall (x) within ten (10) days after
the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such
request is given by the Initiating Holders, file a Form F-1 registration statement under the Securities Act covering all 

  
 4 

 
Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as
specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(b) Form F-3 Demand. If at any time when it is eligible to use a Form F-3 registration statement, the Company receives a request from
(i) Holders of at least sixty percent (60%) of the Preferred B Shares or (ii) the Requisite New Investors that the Company file a Form F-3 registration statement with respect to outstanding Registrable Securities of such Holders
having an anticipated aggregate offering price, net of Selling Expenses, of at least $1.0 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the
Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form F-3 registration statement under the Securities Act covering all
Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject
to the limitations of Subsections 2.1(c) and 2.3. 
 (c) Notwithstanding the foregoing obligations, if the Company furnishes
to Holders requesting a registration pursuant to Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Management Board it would be materially
detrimental to the Company and its shareholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would
(i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business
purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any
time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than sixty (60) days after the request of the Initiating Holders is given; provided, however, that the Company
may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other shareholder during such sixty (60) day
period other than an Excluded Registration. 
 (d) The Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to Subsection 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after
the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has
effected one registration pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form F-3 pursuant to a

  
 5 

 
request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b)
(i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration,
provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to
Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as
the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand
registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2 Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for
shareholders other than the Holders) any of its Common Shares or American Depositary Shares under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company
shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection
2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this
Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be
borne by the Company in accordance with Subsection 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the
Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if
the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of securities to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities
that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall 

  
 6 

 
be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder
or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless
all other securities are first entirely excluded from the underwriting. To facilitate the allocation of securities in accordance with the above provisions, the Company or the underwriters may round the number of securities allocated to any Holder to
the nearest one hundred (100) securities. 
 (b) In connection with any offering involving an underwriting pursuant to Subsection
2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only
in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by shareholders to be included in
such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than
all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable
to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of securities in accordance with the above provisions, the
Company or the underwriters may round the number of securities allocated to any Holder to the nearest one hundred (100) securities. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the
offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty
percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other
shareholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the
partners, members, retired partners, retired members, shareholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any
of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons
included in such “selling Holder,” as defined in this sentence. 
 (c) For purposes of Subsection 2.1, a registration
shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have
requested to be included in such registration statement are actually included. 

  
 7 

 2.4 Obligations of the Company. Whenever required under this Section 2 to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file
with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the
Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed;
provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Shares (or other securities) of
the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with
applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to 120 days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any
such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

  
 8 

 (g) provide a transfer agent and registrar, or a depositary in the case of American Depositary
Shares, for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to
such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company’s supervisory board members, management board members, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary
or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s supervisory board members may implement a trading program under Rule 10b5-1 of the Exchange Act. 

2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of
such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6 Expenses of
Registration. To the extent permitted by law, all expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification
fees; printers’ and accounting fees; all fees and expenses related to the deposit of Common Shares with a depositary for American Depositary Receipts representing Common Shares to be registered or otherwise (including in connection with any
sale or distribution and including Common Shares not registered); fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling Holders (“Selling Holder Counsel”), shall
be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently
withdrawn at the request of the Holders 

  
 9 

 
of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be
included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided
further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have
withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or
2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.

 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this Section 2: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers,
directors, and shareholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the
meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in
connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(a) shall not apply
to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that
they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use
in connection with such registration. 
 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify
and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the
Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent
that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written 

  
 10 

 
information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that
the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be
unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering
received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including
any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying
party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been
given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one
counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due
to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such
action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure
to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate
losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in
connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect 

  
 11 

 
any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue
or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access
to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such
Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to
contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid
or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this
Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form F-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times
after the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable efforts to file
with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to 

  
 12 

 
such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form F-3 (at any time after the Company so
qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has
become subject to the reporting requirements under the Exchange Act) or pursuant to Form F-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. Prior to the IPO, the Company shall not, without the prior written consent of the
Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would provide to such holder the right to include securities in any
registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities that
they wish to so include; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 3.9. 

2.11 “Market Stand-off” Agreement. Each Holder hereby agrees that it will not,
without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of its Common Shares (or American Depositary Shares in respect thereof) or
any other equity securities under the Securities Act in connection with its IPO, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, or such other period as may
be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the
restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or
contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Shares (or American Depositary Shares in respect thereof) or any securities convertible into or
exercisable or exchangeable (directly or indirectly) for Common Shares (whether such shares or any such securities are then owned by the Holder or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Shares or other securities, in cash,
or otherwise. The foregoing provisions of this Subsection 2.11 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to an Affiliate or any trust for the direct
or indirect benefit of the Holder or the immediate family of the Holder, provided that such Affiliate or trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such
transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar agreement
from shareholders owning at least one percent (1%) of the Company’s outstanding Common Shares (after giving effect to conversion into Common Shares of all outstanding preferred shares). In addition, the restrictions of this Subsection
2.11 shall not 

  
 13 

 
prohibit the transfer or sale of any securities acquired by the undersigned in the IPO (other than any Company directed securities purchased in the IPO by an officer or director of the Company)
or in open market transactions after the completion of the IPO if and only if (i) such transfers or sales are not required to be reported in any public report or filing with the SEC under Section 13 or Section 16 of the Exchange Act;
and (ii) the undersigned does not otherwise voluntarily effect any filing under Section 13 or Section 16 of the Exchange Act during the 180-day lock-up period regarding such transfers or sales. The underwriters in connection with such
registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder
further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto. 

2.12 Restrictions on Transfer. 

(a) The Common Shares (or American Depositary Shares in respect thereof), the Preferred B Shares and the Registrable Securities shall not be
sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent, if any, with respect to any such sale, pledge, or transfer, except
upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Common Shares (or
American Depositary Shares in respect thereof), the Preferred B Shares and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

(b) Each certificate, instrument, or book entry representing (i) the Preferred B Shares, (ii) the Registrable Securities,
(iii) the American Depositary Shares and (iii) any other securities issued in respect of the securities referenced in clauses (i), (ii) and (iii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or
similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE SHAREHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

  
 14 

 The Holders consent to the Company making a notation in its records and giving instructions to
any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of
this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give
notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested
by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect
that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or
transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the
terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no
consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall
be notated with the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the
Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 
 2.13 Termination of
Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares
without limitation during a three-month period without registration; 
 (b) the third anniversary of the IPO; and 

(c) the fifth anniversary of this Agreement. 

  
 15 

 3. Miscellaneous. 

3.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (i) is an Affiliate of a Holder; or (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members;
provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights
are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. The terms and
conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

3.2 Governing Law. This Agreement shall be governed by, and interpreted in accordance with, Delaware law, excluding its conflict of
laws rules. 
 3.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have
been duly and validly delivered and be valid and effective for all purposes.  
 3.4 Titles and Subtitles. The titles
and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. 

3.5 Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed
effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during
normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the
business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth
on Schedule A or Schedule B (as applicable) hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as
subsequently modified by written notice given in accordance with this Subsection 3.5. If notice is given to the Company, a copy shall also be sent to Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New
York, NY, 10007, Attention: Brian A. Johnson, telephone: 212-937-7206, facsimile: 212-230-8888 and to Freshfields Bruckhaus Deringer, Seilergasse 16, 1010 Vienna, Austria, Attention: Thomas Zottl, telephone: +43-1-51515-209, facsimile:
+43-1-51515-409. 

  
 16 

 3.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance
of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Requisite New Investors; provided that the Company may
in its sole discretion waive compliance with Subsection 2.12(c); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.
Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or
waiver applies to all Investors in the same fashion. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such
term, condition, or provision. 
 3.7 Severability. In case any one or more of the provisions contained in this Agreement is for any
reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and
construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 3.8 Aggregation of Stock. All
shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves
in any manner they deem appropriate. 
 3.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the
Company issues additional Preferred B Shares after the date hereof, whether pursuant to the Subscription Agreement or otherwise, any purchaser of Preferred B Shares may become a party to this Agreement by executing and delivering an additional
counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor,
so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

3.10 Entire Agreement. This Agreement (including any Exhibits hereto) constitutes the full and entire understanding and agreement
among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. For the avoidance of doubt, Sections 4.7.1, 4.7.2, 4.7.3
and 4.7.4 of the Shareholders Agreement are hereby terminated. 
 3.11 Dispute Resolution. The parties agree that all disputes
arising out of this Agreement or related to its violation, termination or nullity shall be finally settled in accordance with Section 12.2 of the Shareholders Agreement. 

  
 17 

 3.12 Delays or Omissions. No delay or omission to exercise any right, power, or remedy
accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or
acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All
remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 3.13
Acknowledgment by the Company. The Company acknowledges that the Investors are in the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises
which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or
not such enterprise has products or services which compete with those of the Company. 
 [Remainder of Page Intentionally Left Blank]

  
 18 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

									
		 		 		 	COMPANY:
				
		 		 		 	NABRIVA THERAPEUTICS AG:
					
		 		 		 	By:	 	 /s/ Ralf Schmid

		 		 		 	Name:	 	 Ralf Schmid

		 		 		 	Title:	 	 Chief Financial Officer, Chief Operating Officer

				
		 		 		 	SHAREHOLDERS:
				
		 		 		 	SANDOZ GMBH
					
	By:	 	 /s/ Hubert Hirzinger
	 		 	By:	 	 /s/ Chris Mader

	 Name:
	 	 Hubert Hirzinger
	 		 	Name:	 	 Chris Mader

	 Title:
	 	 Chief Financial Officer, Managing Director
	 		 	Title:	 	 Head Legal

				
		 		 		 	GERD ASCHER
					
		 		 		 	By:	 	 /s/ Gerd Ascher

		 		 		 	Name:	 	 Gerd Ascher

		 		 		 	Title:	 	 Ph.D.

				
		 		 		 	RODGER NOVAK
					
		 		 		 	By:	 	 /s/ Rodger Novak

		 		 		 	Name:	 	 Rodger Novak

		 		 		 	Title:	 	 Founder

				
		 		 		 	PHASE4 VENTURES III L.P.
					
		 		 		 	By:	 	 /s/ Denise Pollard-Knight

		 		 		 	Name:	 	 Denise Pollard-Knight

		 		 		 	Title:	 	 Managing Partner

				
		 		 		 	WELLCOME TRUST LIMITED
					
		 		 		 	By:	 	 /s/ Nick Moakes

		 		 		 	Name:	 	 Nick Moakes

		 		 		 	Title:	 	 Managing Director of Investments

  
 [Signature Page to
Registration Rights Agreement] 

									
							HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD
					
							By:		 /s/ Jean Marc LeSieur

							Name:		 Jean Marc LeSieur

							Title:		 Director

				
							HBM BIOCAPITAL INVEST LTD.
					
							By:		 /s/ Jean Marc LeSieur

							Name:		 Jean Marc LeSieur

							Title:		 Director

				
							NOVARTIS BIOVENTURES, LTD.
					
	By:		 /s/ H. S. Zivi
				By:		 /s/ Laurieann Chaikowsky

	Name:		 H. S. Zivi
				Name:		 Laurieann Chaikowsky

	Title:		 Chairman
				Title:		 Authorized Signatory

				
							DAVID CHISWELL
					
							By:		 /s/ David Chiswell

							Name:		 David Chiswell

							Title:		  

				
							VIVO CAPITAL FUND VIII, L.P.
					
							By:		 /s/ Frank Kung

							Name:		 Frank Kung

							Title:		 Director

				
							VIVO CAPITAL SURPLUS FUND VIII, L.P.
					
							By:		 /s/ Frank Kung

							Name:		 Frank Kung

							Title:		 Director

  
 [Signature Page to
Registration Rights Agreement] 

									
		 		 		 	ORBIMED PRIVATE INVESTMENTS V, LP
					
	By:	 	 /s/ Chau Q. Khuong
	 		 	By:	 	 /s/ Edwin Denekamp

	Name:	 	 Chau Q. Khuong
	 		 	Name:	 	 Edwin Denekamp

	Title:	 	 Director A
	 		 	Title:	 	 Director B

				
		 		 		 	GLOBAL LIFE BIOVENTURE IV S.A.R.L.
					
	By:	 	 /s/ Matthijs Bogers
	 		 	By:	 	 /s/ Richard Lim

	Name:	 	 Matthijs Bogers
	 		 	Name:	 	 Richard Lim

	Title:	 	 Manager
	 		 	Title:	 	 Manager B

				
		 		 		 	ECOR1 CAPITAL FUND, L.P.
					
		 		 		 	By:	 	 /s/ Oley Nodelman

		 		 		 	Name:	 	 Oley Nodelman

		 		 		 	Title:	 	 Managing Director

				
		 		 		 	ECOR1 CAPITAL FUND QUALFIED, L.P.
					
		 		 		 	By:	 	 /s/ Oley Nodelman

		 		 		 	Name:	 	 Oley Nodelman

		 		 		 	Title:	 	 Managing Director

				
		 		 		 	BOXER CAPITAL, LLC
					
		 		 		 	By:	 	 /s/ Aaron Davis

		 		 		 	Name:	 	 Aaron Davis

		 		 		 	Title:	 	 Chief Executive Officer

				
		 		 		 	CLOUDWOOD TRUST
				
		 		 		 	By: Intertrust Trustees Ltd., its trustee
					
	By:	 	 /s/ Julia Church
	 		 	By:	 	 /s/ Grant Howitt

	Name:	 	 Julia Church
	 		 	Name:	 	 Grant Howitt

	Title:	 	 Authorized Signatory
	 		 	Title:	 	 Authorized Signatory

  
 [Signature Page to
Registration Rights Agreement] 

									
		 		 		 	RALF SCHMID
					
		 		 		 	By:	 	 /s/ Ralf Schmid

		 		 		 	Name:	 	 Ralf Schmid

		 		 		 	Title:	 	 Chief Financial Officer, Chief Operating Officer

				
		 		 		 	WILLIAM PRINCE
					
		 		 		 	By:	 	 /s/ William Prince

		 		 		 	Name:	 	 William Prince

		 		 		 	Title:	 	 Senior Vice President

				
		 		 		 	ARAX 2009.EINS PRIVATE EQUITY GMBH & CO KG
					
	 By:
	 	 /s/ Beatrix Schuberth
	 		 	By:	 	 /s/ Michael Stranz

	 Name:
	 	 Beatrix Schuberth
	 		 	Name:	 	 Michael Stranz

	 Title:
	 	 Managing Director
	 		 	Title:	 	 Managing Director

				
		 		 		 	ARAX 2010 PRIVATE EQUITY GMBH & CO KG
					
	 By:
	 	 /s/ Beatrix Schuberth
	 		 	By:	 	 /s/ Michael Stranz

	 Name:
	 	 Beatrix Schuberth
	 		 	Name:	 	 Michael Stranz

	 Title:
	 	 Managing Director
	 		 	Title:	 	 Managing Director

				
		 		 		 	ARAX 2010.EINS PRIVATE EQUITY GMBH & CO KG
					
	By:	 	 /s/ Beatrix Schuberth
	 		 	By:	 	 /s/ Michael Stranz

	Name:	 	 Beatrix Schuberth
	 		 	Name:	 	 Michael Stranz

	Title:	 	 Managing Director
	 		 	Title:	 	 Managing Director

				
		 		 		 	KREOS CAPITAL III LIMITED
					
		 		 		 	By:	 	 /s/ Raoul Stein

		 		 		 	Name:	 	 Raoul Stein

		 		 		 	Title:	 	 Director

  
 [Signature Page to
Registration Rights Agreement] 

 
											
		 		 		 		 	GEORGE TALBOT
						
		 		 		 		 	By:	 	 /s/ George H. Talbot, MD

		 		 		 		 	Name:	 	 George H. Talbot, MD

		 		 		 		 	Title:	 	  

					
		 		 		 		 	COLIN BROOM
						
		 		 		 		 	By:	 	 /s/ Colin Broom

		 		 		 		 	Name:	 	 Colin Broom

		 		 		 		 	Title:	 	 Chief Executive Officer

					
		 		 		 		 	HTBT GMBH & CO KG
					
		 		 		 		 	By: ARAX Capital Partners GmbH, its General Partner
						
	By:	 	 /s/ Beatrix Schuberth
	 		 		 	By:	 	 /s/ Michael Stranz

	Name:	 	 Beatrix Schuberth
	 		 		 	Name:	 	 Michael Stranz

	Title:	 	 Managing Director
	 		 		 	Title:	 	 Managing Director

					
		 		 		 		 	BTHT GMBH & CO KG
					
		 		 		 		 	By: ARAX Capital Partners GmbH, its General Partner
						
	By:	 	 /s/ Beatrix Schuberth
	 		 		 	By:	 	 /s/ Michael Stranz

	Name:	 	 Beatrix Schuberth
	 		 		 	Name:	 	 Michael Stranz

	Title:	 	 Managing Director
	 		 		 	Title:	 	 Managing Director

  
 [Signature Page to
Registration Rights Agreement] 

 SCHEDULE A 

New Investors 
 Vivo Capital Fund VIII,
L.P. 
 575 High Street, Suite 201 
 Palo Alto, CA 94301 

United States 
 Telephone: +1 650-688-0818 

Facsimile: +1 650-688-0815 
 Vivo Capital Surplus Fund VIII, L.P.

 575 High Street, Suite 201 
 Palo Alto, CA 94301 

United States 
 Telephone: +1 650-688-0818 

Facsimile: +1 650-688-0815 
 OrbiMed Private Investments V, LP

 601 Lexington Avenue 
 New York, NY 10022 

United States 
 Telephone: +1 212-739-6400 

Facsimile: +1 212-739-6444 
 HBM Healthcare Investments (Cayman)
Ltd. 
 Bundesplatz 1 
 CH-6300 Zug 

Switzerland 
 Telephone: +41 43 888 71 10 

Telecopier: +41 43 888 71 72 
 Global Life Bioventure IV S.a.r.l.

 c/o Amicorp Luxembourg S.A. 
 11-13, Boulevard de la Foire

 L-1528 Luxembourg 
 Grand Duchy of Luxembourg 

Telephone: +352 262743-1 
 Facsimile: +352 262 743 50 

EcoR1 Capital Fund, L.P. 
 409 Illinois Street 

San Francisco, CA 94158 
 United States 

Telephone: +1 415-754-3517 

 EcoR1 Capital Fund Qualfied, L.P. 

409 Illinois Street 
 San Francisco, CA 94158 

United States 
 Telephone: +1 415-754-3517 

Boxer Capital, LLC 
 440 Stevens Avenue, Suite 100 

Solana Beach, CA 92075 
 United States 

Telephone: +1 858-400-3112 
 Phase4 Ventures III L.P. 

15 Stratton Street 
 London W1J 8LQ 

United Kingdom 
 Telephone: +44 203 036 0350 

Wellcome Trust Limited 
 215 Euston Road 

London NW1 2BE 
 United Kingdom 

Telephone: +44 207 611 8666 
 Telecopier: +44 207 611 7268 

Novartis Bioventures, Ltd. 
 131 Front Street 

Hamilton, Bermuda 
 Telephone: +1 441 296 8025 

Telecopier: +1 441 296 5083 

 SCHEDULE B 

Initial Investors 
 Phase4 Ventures III
L.P. 
 15 Stratton Street 
 London W1J 8LQ 

United Kingdom 
 Telephone: +44 203 036 0350 

Wellcome Trust Limited 
 215 Euston Road 

London NW1 2BE 
 United Kingdom 

Telephone: +44 207 611 8666 
 Telecopier: +44 207 611 7268 

HBM Healthcare Investments (Cayman) Ltd. 
 Bundesplatz 1 

CH-6300 Zug 
 Switzerland 

Telephone: +41 43 888 71 10 
 Telecopier: +41 43 888 71 72 

HBM BioCapital Invest Ltd. 
 Bundesplatz 1 

CH-6300 Zug 
 Switzerland 

Telephone: +41 43 888 71 10 
 Telecopier: +41 43 888 71 72 

Novartis Bioventures, Ltd. 
 131 Front Street 

Hamilton, Bermuda 
 Telephone: +1 441 296 8025 

Telecopier: +1 441 296 5083 
 Kreos Capital III Limited 

25-28 Old Burlington Street 
 London, W1S 3AN 

Telephone: +44 20 7758 3450 
 Telecopier: +44 20 7409 1034 

Arax 2009 
 ARAX Capital Partners GmbH 

Handelskai 94-96/OG 9. 

 A-1200 Vienna 

Austria 
 Telephone: +43 1 370 74 74 0 

Telecopier: +43 1 370 74 74 22 
 Arax 2010 

ARAX Capital Partners GmbH 
 Handelskai 94-96/OG 9. 

A-1200 Vienna 
 Austria 

Telephone: +43 1 370 74 74 0 
 Telecopier: +43 1 370 74 74 22 

Arax 2010 eins 
 ARAX Capital Partners GmbH 

Handelskai 94-96/OG 9. 
 A-1200 Vienna 

Austria 
 Telephone: +43 1 370 74 74 0 

Telecopier: +43 1 370 74 74 22 
 HTBT 

ARAX Capital Partners GmbH 
 Handelskai 94-96/OG 9. 

A-1200 Vienna 
 Austria 

Telephone: +43 1 370 74 74 0 
 Telecopier: +43 1 370 74 74 22 

BTHT 
 ARAX Capital Partners GmbH 

Handelskai 94-96/OG 9. 
 A-1200 Vienna 

Austria 
 Telephone: +43 1 370 74 74 0 

Telecopier: +43 1 370 74 74 22 
 Sandoz GmbH 

Biochemiestrasse 10 
 6250 Kundl 

Austria 
 Telephone: +43 5338 200 2207 

Telecopier: +43 5338 8828 

 David Chiswell 

Leberstraße 20, A-1110 Vienna 
 Austria 

Telephone: +44 771 114 2858 
 Telecopier: +43 1 74093 1900 

Gerd Ascher 
 Pyrkergasse 15/1a+b 

1190 
 Austria 

Telephone: +43 6766 100 324 
 Rodger Novak 

Apollogasse 26/26 
 1070 Vienna 

Austria 
 Telephone: +43 664 867 928 

Telecopier: +43 1 74093 1900 
 Ralf Schmid 

Leberstraße 20 
 A-1112 Vienna 

Austria 
 Telephone: +44 771 114 2858 

Telecopier: +43 1 74093 1900 
 William Prince 

Leberstraße 20 
 A-1112 Vienna 

Austria 
 Telephone: +44 771 114 2858 

Telecopier: +43 1 74093 1900 
 Cloudwood Trust 

PO Box 119 
 Martello Court 

Admiral Park 
 St. Peter Port 

Guernsey GY1 3HB 
 Telephone: +44 1481 211 000 

Telecopier: +44 1481 211 001 
 George Talbot 

Leberstraße 20 
 A-1112 Vienna 

Austria 
 Telephone: +44 771 114 2858 

Telecopier: +43 1 74093 1900 

 Colin Broom 

Leberstraße 20 
 A-1112 Vienna 

Austria 
 Telephone: +44 771 114 2858 

Telecopier: +43 1 74093 1900

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]